Status:
COMPLETED
Safety and Efficacy of Albiglutide in Type 2 Diabetes
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
Eligibility Criteria
Inclusion
- type 2 diabetes
- BMI 20-45kg/m2
Exclusion
- NYHA Class II to IV heart failure
- females who are pregnant, lactating, or less than 6 weeks post-partum
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT00849056
Start Date
January 1 2009
End Date
January 1 2013
Last Update
January 9 2017
Active Locations (331)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Alabaster, Alabama, United States, 35007
2
GSK Investigational Site
Birmingham, Alabama, United States, 35205
3
GSK Investigational Site
Birmingham, Alabama, United States, 35235
4
GSK Investigational Site
Birmingham, Alabama, United States, 35242